283 related articles for article (PubMed ID: 15963044)
21. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
[TBL] [Abstract][Full Text] [Related]
22. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein.
Guo L; Zheng M; Ding Y; Li D; Yang Z; Wang H; Chen Q; Sui Z; Fang F; Chen Z
Arch Virol; 2010 Nov; 155(11):1765-75. PubMed ID: 20652335
[TBL] [Abstract][Full Text] [Related]
23. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine.
Tamura SI; Asanuma H; Ito Y; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T; Oya A
Eur J Immunol; 1992 Feb; 22(2):477-81. PubMed ID: 1537382
[TBL] [Abstract][Full Text] [Related]
24. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
[TBL] [Abstract][Full Text] [Related]
25. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.
Bakke H; Samdal HH; Holst J; Oftung F; Haugen IL; Kristoffersen AC; Haugan A; Janakova L; Korsvold GE; Krogh G; Andersen EA; Djupesland P; Holand T; Rappuoli R; Haneberg B
Scand J Immunol; 2006 Mar; 63(3):223-31. PubMed ID: 16499576
[TBL] [Abstract][Full Text] [Related]
26. Studies on the usefulness of intranasal inactivated influenza vaccines.
Tamura S
Vaccine; 2010 Aug; 28(38):6393-7. PubMed ID: 20493820
[TBL] [Abstract][Full Text] [Related]
27. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity.
Arulanandam BP; O'Toole M; Metzger DW
J Infect Dis; 1999 Oct; 180(4):940-9. PubMed ID: 10479116
[TBL] [Abstract][Full Text] [Related]
28. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
[TBL] [Abstract][Full Text] [Related]
29. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
[TBL] [Abstract][Full Text] [Related]
30. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine.
Isaka M; Komiya T; Takahashi M; Yasuda Y; Taniguchi T; Zhao Y; Matano K; Matsui H; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2004 Aug; 22(23-24):3061-8. PubMed ID: 15297056
[TBL] [Abstract][Full Text] [Related]
31. [Comparative studies on the vaccination of mice with inactivated influenza virus administered by the aerosol technique, by the intranasal or intramuscular route (author's transl)].
Neukirch M; Bauer K; Barth S
Zentralbl Bakteriol Orig A; 1979 Dec; 245(4):409-20. PubMed ID: 44935
[TBL] [Abstract][Full Text] [Related]
32. Antibody response in mice immunized by mucosal routes with formalin-inactivated enteropathogenic Escherichia coli (EPEC) strains.
Drago-Serrano ME; Manjarréz Hernandez HA; Gavilanes Parra S; Sainz Espuñes Tdel R
Rev Latinoam Microbiol; 2004; 46(1-2):17-23. PubMed ID: 17061522
[TBL] [Abstract][Full Text] [Related]
33. Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine.
Berstad AK; Andersen SR; Dalseg R; Dromtorp S; Holst J; Namork E; Wedege E; Haneberg B
Vaccine; 2000 Mar; 18(18):1910-9. PubMed ID: 10699340
[TBL] [Abstract][Full Text] [Related]
34. Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fimbriae and recombinant cholera toxin B subunit.
Takahashi Y; Kumada H; Hamada N; Haishima Y; Ozono S; Isaka M; Yasuda Y; Tochikubo K; Umemoto T
Oral Microbiol Immunol; 2007 Dec; 22(6):374-80. PubMed ID: 17949339
[TBL] [Abstract][Full Text] [Related]
35. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
Greenbaum E; Furst A; Kiderman A; Stewart B; Levy R; Schlesinger M; Morag A; Zakay-Rones Z
J Med Virol; 2001 Sep; 65(1):178-84. PubMed ID: 11505461
[TBL] [Abstract][Full Text] [Related]
36. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.
Asahi Y; Yoshikawa T; Watanabe I; Iwasaki T; Hasegawa H; Sato Y; Shimada S; Nanno M; Matsuoka Y; Ohwaki M; Iwakura Y; Suzuki Y; Aizawa C; Sata T; Kurata T; Tamura S
J Immunol; 2002 Mar; 168(6):2930-8. PubMed ID: 11884464
[TBL] [Abstract][Full Text] [Related]
37. Immune responses and protective efficacy in ponies immunised with an equine influenza ISCOM vaccine containing an 'American lineage' H3N8 virus.
Crouch CF; Daly J; Hannant D; Wilkins J; Francis MJ
Vaccine; 2004 Dec; 23(3):418-25. PubMed ID: 15530689
[TBL] [Abstract][Full Text] [Related]
38. Mucosal immunization of CD4+ T cell-deficient mice with an inactivated virus induces IgG and IgA responses in serum and mucosal secretions.
Sha Z; Kang SM; Compans RW
Virology; 2005 Jan; 331(2):387-95. PubMed ID: 15629781
[TBL] [Abstract][Full Text] [Related]
39. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine.
Lambkin R; Oxford JS; Bossuyt S; Mann A; Metcalfe IC; Herzog C; Viret JF; Glück R
Vaccine; 2004 Oct; 22(31-32):4390-6. PubMed ID: 15474733
[TBL] [Abstract][Full Text] [Related]
40. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
